Vibrio vulnificus Illness Review Subcommittee Report
October 2, 2011

The subcommittee reviewed 2010 cases during conference calls on October 28, 2010, December 8, 2010, January 5, 2011, and most recently on September 28, 2011. As of the time of the last meeting of the Vibrio Management Committee in January 2011, 14 cases had been found to meet the case definition. At that time there had been no reconciliation of case as between CDC and FDA.

In late September FDA and CDC completed their reconciliation of cases and additional case information was provided to the Vv Illness Review Subcommittee. The subcommittee has reviewed those additional cases. After review of all 2010 cases, the subcommittee reports that 17 cases meet the definition. In addition the committee has requested additional information on one additional case.

The subcommittee was also tasked with reviewing those Vv cases from non-Gulf states. The purpose of this review was to determine if other states outside the Gulf are required to have *Vibrio vulnificus* control plans.

The subcommittee discussed that a larger question was whether the same criteria for cases to count toward whether illness reduction goals have been met should also be used to determine if a state will need a management plan. It was uniquely discussed that by the nature of the assignment, only cases attributable to single states could be used for the entry criteria, whereas the criteria for whether a case counts toward illness reduction goals.

Marc Glatzer, FDA, queried the database numerous times and in numerous ways to develop a list of cases for the subcommittee's review. Only cases attributable to single states were included on the list. The list contained 4 cases, two attributed to NJ product and two attributed to Virginia product. After review the subcommittee determined that the NJ cases do not meet the case definition and that the Virginia cases do meet the case definition.